Search

Protagonist Therapeutics Inc

Lezárt

SzektorEgészségügy

142.84 -0.09

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

140.51

Maximum

144.3

Fő mutatók

By Trading Economics

Bevétel

159M

163M

Értékesítés

157M

213M

P/E

Szektor átlag

143.476

56.432

Egy részvényre jutó nyereség

2.29

Profit margin

76.285

Munkavállalók

141

EBITDA

162M

165M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+16.21% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1.1B

9.6B

Előző nyitás

142.93

Előző zárás

142.84

Hangulat hírek alapján

By Acuity

27%

73%

38 / 339 Rangsor szerint Healthcare

Protagonist Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 18. 20:06 UTC

Protagonist Therapeutics Inc shares fell sharply, remaining below their 20-day moving average and near the lower end of their one-month range.

2026. szept. 17. 19:46 UTC

Protagonist Therapeutics Inc shares are trading roughly flat, currently below their opening level and the 20-day moving average after three consecutive lower closes.

2026. szept. 16. 19:13 UTC

Protagonist Therapeutics Inc shares fell sharply amid a broader market decline, influenced by mixed economic data and cautious investor sentiment ahead of jobless claims.

2026. szept. 15. 20:07 UTC

Protagonist Therapeutics shares are lower amid broader market concerns, following a significant drop in the NY Empire State Manufacturing Index for September.

2026. szept. 11. 20:08 UTC

News

Protagonist Therapeutics shares are higher as CEO Dinesh V. Patel exercises options and sells over 70,000 shares, boosting investor sentiment.

2026. szept. 9. 20:07 UTC

News
Social Media

Protagonist Therapeutics announced a $300 million share repurchase program, but shares are trading lower during Wednesday's session after pulling back from an earlier high.

2026. szept. 2. 20:08 UTC

Social Media

Protagonist Therapeutics shares are lower despite Barclays setting a $180 price target following the approval of Mimrylo for polycythemia vera treatment.

2026. szept. 1. 19:36 UTC

News
Social Media

Protagonist Therapeutics shares are lower today, despite analysts raising price targets following the approval of Mimrylo. Barclays set a target of $180.

2026. aug. 28. 20:02 UTC

Protagonist Therapeutics Inc is declining during Friday's session, reversing earlier gains amid rising U.S. Treasury yields and broader market dynamics.

2026. aug. 27. 20:07 UTC

Protagonist Therapeutics Inc shares are lower during Thursday's session, continuing a decline since Wednesday amid broader market conditions and economic resilience signals.

2026. aug. 26. 20:08 UTC

Protagonist Therapeutics Inc shares are trading higher today. No specific news was identified to explain the movement amid mixed broader market conditions.

2026. aug. 25. 23:36 UTC

Protagonist Therapeutics Inc. sees modest gains in after-market trading amid a broader market backdrop of declining crude oil prices and easing geopolitical tensions.

2026. aug. 24. 20:06 UTC

Protagonist Therapeutics shares are higher today, recovering from an earlier dip. The broader market also shows slight gains since Friday's close.

2026. aug. 21. 20:06 UTC

Protagonist Therapeutics Inc is rising during Friday's session, showing steady gains since Thursday amid a broader market boost from Bitcoin's surge.

2026. aug. 20. 19:31 UTC

Correlated Moves

Protagonist Therapeutics Inc shares are lower today amid a decline in the Biotechnology sector, with unusually high trading volume noted during the session.

2026. aug. 19. 19:46 UTC

Protagonist Therapeutics Inc shares are lower today, retracing from earlier highs. The price remains above its 20-day moving average amid no specific news.

2026. aug. 17. 19:46 UTC

Social Media
News

BMO Capital raised Protagonist Therapeutics' price target to $178, maintaining an Outperform rating, as shares trade higher amid positive pipeline developments.

2026. aug. 14. 22:36 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

2026. aug. 13. 20:06 UTC

Correlated Moves
News
Social Media

Protagonist Therapeutics shares are lower amid insider selling concerns following CEO Dinesh V. Patel's recent stock transactions. The decline reflects broader sector trends.

2026. aug. 12. 23:31 UTC

Social Media

Protagonist Therapeutics Inc gains after-market, reaching a high above Wednesday's close. Investor interest grows amid social media discussions on increasing positions.

2026. aug. 11. 23:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement amid earlier volatility and fluctuations.

2026. aug. 10. 23:46 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, with notable strength above the 20-day moving average and near the upper end of its one-month range.

2026. aug. 6. 19:52 UTC

Social Media
News

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

2026. aug. 5. 22:02 UTC

News

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

2026. aug. 4. 21:03 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

2026. aug. 3. 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

2026. júl. 31. 19:36 UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

2026. júl. 30. 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

2026. júl. 29. 19:43 UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

2026. júl. 28. 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

Társak összehasonlítása

Árváltozás

Protagonist Therapeutics Inc Előrejelzés

Célár

By TipRanks

16.21% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 167 USD  16.21%

Magas 186 USD

Alacsony 121 USD

12 Wall Street elemző 12 hónapos célárain alapulva a(z)Protagonist Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

12 ratings

12

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

38 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.